Terlipressin in the management of liver disease

Andrew R. Scheinberg, Paul Martin, Joshua A. Turkeltaub

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Introduction: Terlipressin is a synthetic vasopressin analog which has been recently approved in the United States by the Food and Drug Administration for the treatment of hepatorenal syndrome. Terlipressin stimulates vasopressin receptors located on the smooth muscle vasculature of the splanchnic circulation and renal tubules which results in splanchnic vasoconstriction with improved renal perfusion and antidiuretic activity, respectively. Areas covered: In this review, we discuss available data regarding the FDA approved use of terlipressin, safety, and tolerability, as well as highlight alternative uses in chronic liver disease currently still under investigation. Expert opinion: Terlipressin is more efficacious compared to other vasoactive agents including midodrine octreotide and norepinephrine in reversal of hepatorenal syndrome and improves short-term survival. Other potential applications of terlipressin’s vasoconstrictor actions reported in the literature include management of variceal hemorrhage and other complications of portal hypertension.

Original languageEnglish
Pages (from-to)1665-1671
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Issue number15
StatePublished - 2023
Externally publishedYes


  • Acute-on-chronic liver failure
  • hepatorenal syndrome-acute kidney injury
  • hepatorenal syndrome–1
  • terlipressin
  • vasopressin


Dive into the research topics of 'Terlipressin in the management of liver disease'. Together they form a unique fingerprint.

Cite this